Playtex Simply Gentle Glide heroes simplicity with relaunch, video spoof
Edgewell’s feminine care brand Playtex has launched a short video featuring actress comedian D’Arcy Carden spoofing the fact that, despite the influx of “extras” in today’s society, simple is all you need when it comes to tampons.
“It’s funny how extra things have gotten in everything – from diet crazes, new technology and apps launching seemingly every day, even down to the fem care category. I don’t need a tampon to balance my flora, I need one to absorb my period flow and I love that Playtex Simply Gentle Glide is reminding women to get back to the simple things,” Carden said.
Relaunching in June, the Playtex Simply Gentle Glide line now comes with a clear applicator free from colors, dyes and BPA.
“We felt it was time to speak to our customers with a fresh take on the current conversation happening around feminine care,” said Devon Driscoll, brand manager at Playtex Simply Gentle Glide. “This campaign heroes simplicity and is a reminder to simplify our lives a bit – because, at the end of the day, women want a tampon that is safe, gentle and reliable, and that’s what we offer.”
PMI, Parallax collaborate to focus on alternative nicotine-delivery platforms
Philip Morris International announced on Thursday a strategic collaboration with Canadian-based start-up Parallax to focus on advancing the development and commercialization of a nicotine-delivery system that leverages the advanced technologies in pulmonary medicine.
Parallax is a start-up co-founded by two Canadian pulmonary physicians focused on developing an inhalable nicotine product to provide less harmful alternatives to people who smoke. Since its founding, Parallax has assembled a team of experts in formulation, device design, pharmaceutical quality manufacturing, product research and consumer insights.
Said Manuel Peitsch, PMI’s chief scientific officer, “Science and technology will be essential to a future where all men and women who smoke switch to better alternatives. Our collaboration with Parallax, founded by world-renowned experts in pulmonary research and technology, is another step forward and will give us access to innovative technologies and expertise.”
Steven Ellis, Parallax’s CEO, added, “Our team couldn’t be more excited about this next step in our journey – working with the global leader in smoke-free innovation and collaborating with its scientific team in fulfilling our joint mission of replacing what we all know is the most harmful delivery system for nicotine — the cigarette — with innovative alternatives that clearly move smokers to a better place in the harm reduction continuum.”
PMI’s aspiration is that at least 30 percent of its consumers, some 40 million men and women, will switch to its smoke-free products by 2025.
CRN issues voluntary guidelines on SARMs, caffeine-infused supplements
In light of growing concerns on the dangers of products containing selective androgen receptor modulators (SARMs) and caffeine-containing dietary supplements, the Council for Responsible Nutrition announced on Thursday that it has issued new voluntary guidelines.
“CRN’s membership is committed to consumer safety and understands the gravity of going above and beyond what is required by law to ensure their products are high-quality, consistent, and supported by sound science,” said Steve Mister, president and CEO of CRN. “Consumer access to bulk amounts of highly-concentrated powder or liquid caffeine and performance enhancing products containing SARMs are current subjects of sharp industry scrutiny. CRN is grateful for FDA’s recent consumer advisories on these ingredients, as well as for guidance providing clarity to companies attempting to navigate the industry’s strict regulatory framework. CRN’s voluntary guidelines align with FDA’s enforcement actions and help the dietary supplement industry stay on the right side of the law.”
The newly developed guidelines for products containing SARMs stem from increasing concerns raised by FDA, the U.S. Anti-Doping Agency, and the legitimate dietary supplement industry about the dangers of SARMs found in products mis-marketed as dietary supplements. Among the challenges the industry faces with respect to SARMs is the introduction of substances that do not appear to meet the definition of a dietary ingredient as outlined by the United States Federal Food, Drug, and Cosmetic Act; fail to provide proper notification to FDA as new dietary ingredients (NDI); and appear to lack scientific evidence supporting safety, CRN stated. Coinciding with FDA’s position that products containing SARMs do not meet the definition of a dietary supplement, CRN’s guidelines recommend that firms should not distribute or market products containing these ingredients.
CRN’s guidelines for caffeine-containing dietary supplements, originally created in 2013, recommend that companies disclose the amount of caffeine in a dietary supplement, provide label advisories about safe use of such products, and refrain from sale under certain conditions. The guidelines were updated in 2015 to institute restraints against the sale and marketing of bulk amounts of pure or highly-concentrated caffeine in powder form, and the 2018 revisions expand these restraints to also include concentrated liquid forms, as outlined by an FDA guidance released earlier this year.
“CRN trusts that the dietary supplement industry will adopt these two sets of crucial guidelines into its standard operating procedures,” said Mister. “As the marketplace continues to grow and innovate, we lend our full support to FDA’s proactive enforcement efforts to improve consumer safety and industry accountability.”